Race to Develop H1N1 Vaccine

Business of Biotech

Execs from Inovio Biomedical Corporation and Novavax will be speaking at BIF about their experience in the race to develop a vaccine for H1N1. Below are a couple recent developments from these companies:

  • Novavax Inc (NVAX.O) recently reported that its seasonal flu vaccine candidate, which uses virus-like particles, induced an immune response against H3N2, H1N1 and B and was well-tolerated in a mid-stage trial. Read the release.
  • Inovio Biomedical Corp. (INO) said it will team up with the National Institutes of Health’s vaccine-research center to create influenza vaccines and expedite development of an H1N1 vaccine as the pandemic spreads. Read the release.
Business of Biotech  |  Email This Post  |  Printer Friendly
Tags: , , , , , ,

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>